keyword
MENU ▼
Read by QxMD icon Read
search

cardiovascular events in systemic lupus

keyword
https://www.readbyqxmd.com/read/29729450/new-use-for-an-old-treatment-hydroxychloroquine-as-a-potential-treatment-for-systemic-vasculitis
#1
REVIEW
Alina Casian, Shirish Sangle, David P D'Cruz
Antimalarials have been an effective and safe treatment for autoimmune rheumatic diseases such as systemic lupus erythematosus for more than a hundred years. There are surprisingly few reports of hydroxychloroquine use in the systemic vasculitides. Hydroxychloroquine has antithrombotic, cardiovascular, antimicrobial and antineoplastic effects, making it a potentially valuable treatment for patients with systemic vasculitis who are at risk of infections, malignancy and thrombotic events. We report the successful use of hydroxychloroquine in patients with ANCA vasculitis, Henoch Schonlein purpura/IgA vasculitis, Takayasu's arteritis and polyarteritis nodosa...
May 2, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29723220/disease-activity-autoantibodies-and-inflammatory-molecules-in-serum-and-cerebrospinal-fluid-of-patients-with-systemic-lupus-erythematosus-and-cognitive-dysfunction
#2
Alí Duarte-García, Juanita Romero-Díaz, Sandra Juárez, Alba Cicero-Casarrubias, Hilda Fragoso-Loyo, Carlos Núñez-Alvarez, Luis Llorente, Jorge Sánchez-Guerrero
OBJECTIVE: To determine if cognitive dysfunction in patients with systemic lupus erythematosus (SLE) derives from an inflammatory process with continuing disease activity, and increased levels of autoantibodies and inflammatory molecules in serum and cerebrospinal fluid (CSF). METHODS: 100 randomly selected patients participating in an inception SLE cohort were studied. At entry into the cohort, a standardized medical history and extensive laboratory tests profile, including autoantibodies were completed...
2018: PloS One
https://www.readbyqxmd.com/read/29707880/risk-factors-for-adverse-maternal-and-perinatal-outcomes-in-women-with-preeclampsia-analysis-of-1396-cases
#3
Xun Li, Weishe Zhang, Jianhua Lin, Huai Liu, Zujing Yang, Yincheng Teng, Si Duan, Xinxiu Lin, Yingming Xie, Yuanqiu Li, Liangqun Xie, Qiaozhen Peng, Lu Xia
Preeclampsia is a major cause of adverse maternal and perinatal outcomes, but how to identify women and fetuses at increased risk for later adverse events is a challenge. This study aimed to investigate the risk factors for adverse maternal and perinatal outcomes in women with preeclampsia. Data from 1396 women with preeclampsia were retrospectively collected and analyzed. Eighteen candidate risk factors and 12 adverse outcomes were investigated. The following factors were found to be significantly associated with at least one adverse outcome: maternal age 35 years or older, multiple birth, the usage of assisted reproductive technology, living in a rural area, history of pregnancy-induced hypertension, male fetus, multigravida, or having polycystic ovary syndrome, hemolysis, elevated liver enzymes, and low platelet count syndrome, intrahepatic cholestasis of pregnancy, cardiovascular disease, gestational diabetes mellitus, systemic lupus erythematosus, thyroid disease, or liver disease...
April 30, 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29670462/protective-effects-of-hydroxychloroquine-against-accelerated-atherosclerosis-in-systemic-lupus-erythematosus
#4
REVIEW
Alberto Floris, Matteo Piga, Arduino Aleksander Mangoni, Alessandra Bortoluzzi, Gian Luca Erre, Alberto Cauli
Cardiovascular (CV) morbidity and mortality are a challenge in management of patients with systemic lupus erythematosus (SLE). Higher risk of CV disease in SLE patients is mostly related to accelerated atherosclerosis. Nevertheless, high prevalence of traditional cardiovascular risk factors in SLE patients does not fully explain the increased CV risk. Despite the pathological bases of accelerated atherosclerosis are not fully understood, it is thought that this process is driven by the complex interplay between SLE and atherosclerosis pathogenesis...
2018: Mediators of Inflammation
https://www.readbyqxmd.com/read/29571422/atherosclerotic-heart-disease-in-women-with-autoimmune-rheumatologic-inflammatory-conditions
#5
REVIEW
Reto D Kurmann, Rekha Mankad
Women have a higher prevalence of several inflammatory rheumatologic conditions. These include systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc) to name a few. These conditions are all associated with higher rates of cardiovascular (CV) morbidity and mortality, which is driven primarily by atherosclerotic heart disease. Traditional risk factors are important considerations in the assessment of CV risk in the rheumatologic patient; however, these factors do not appear to impart a similar weight of risk in women with inflammatory autoimmune rheumatologic conditions...
April 2018: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29542419/endothelial-dysfunction-in-systemic-lupus-erythematosus-pathogenesis-assessment-and-therapeutic-opportunities
#6
Alessandra Nerviani, Daniele Mauro
Systemic lupus erythematosus (SLE) is characterised by increased mortality secondary to cardiovascular diseases (CVD). Despite being common in SLE, traditional cardiovascular risk factors cannot entirely justify such increase in CVD-associated mortality. The endothelium is a key regulator of the vascular homeostasis; lupus-associated persistent systemic inflammation may impair endothelium functionality, thus initiating a cascade of events that, in concert with traditional CVD-risk factors, leads to atherosclerosis development and progression...
March 13, 2018: Reviews on Recent Clinical Trials
https://www.readbyqxmd.com/read/29447937/splenectomy-may-have-more-complications-than-currently-proven
#7
Somayeh Zakeri, Narjes Gorji, Marjan Akhtari, Reihaneh Moeini
The spleen has been one of the least understood major organs for centuries. Its significance is relatively well-known today but it seems that all aspects of its activities are not fully understood. Persian medicine (PM) has special views on the function of spleen; many side effects were reported in PM due to spleen dysfunction. On the other hand nowadays splenectomy as a treatment strategy is recommended for some disorders and increasing risk of infections is considered as the most important long term side effect of that...
March 2018: Medical Hypotheses
https://www.readbyqxmd.com/read/29428197/therapeutic-impact-of-statins-on-the-lipid-profile-and-cardiovascular-risk-in-patients-with-systemic-lupus-erythematosus-systematic-review-of-the-literature-and-a-meta-analysis
#8
Paula Sánchez, Esteban Toro-Trujillo, Oscar M Muñoz-Velandia, Angel Alberto García, Daniel G Fernández-Ávila
BACKGROUND: There is strong evidence of a rise in cardiovascular risk in patients suffering from autoimmune diseases, especially in those with Sistemic Lupus Erythematosus. Until now, there are a few trials that assess the potencial benefit of statins on the incidence of cardiovascular events and on lipid profile of patients with SLE. This evidence has not been synthesized and assessed altogether. METHODS: We performed a search in databases of literature published until August of 2016 (Embase, MEDLINE, Cochrane Library, SciELO, Clinical Evidence, DynaMed, Cochrane Central Register of Controlled Trials, LILACS), identifying controlled clinical trials that could estimate the impact of statins on mortality, cardiovascular events, C-reactive protein and lipid profile in patients with Systemic Lupus Erythematosus...
February 7, 2018: Reumatología Clinica
https://www.readbyqxmd.com/read/29245186/endothelial-dysfunction-in-early-systemic-lupus-erythematosus-patients-and-controls-without-previous-cardiovascular-events
#9
Mara Taraborelli, Edoardo Sciatti, Ivano Bonadei, Vincenzo Terlizzi, Micaela Fredi, Roberta Zani, Giovanni Cancarini, Angela Tincani, Franco Franceschini, Enrico Vizzardi, Ilaria Cavazzana
OBJECTIVES: To assess the prevalence and risk factors for endothelial dysfunction detected by peripheral artery tonometry in systemic lupus erythematosus patients with early disease without cardiovascular disease and risk factors. METHODS: All the consecutive adult lupus patients, with a disease duration less than 5 years, seen in our Hospital from December 2014 to March 2016 were considered. We excluded patients with any history of cardiovascular disease or risk factors possibly affecting peripheral artery tonometry...
December 15, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29230625/systemic-lupus-erythematosus-and-the-risk-of-perioperative-major-adverse-cardiovascular-events
#10
Nathaniel R Smilowitz, Gregory Katz, Jill P Buyon, Robert M Clancy, Jeffrey S Berger
Systemic lupus erythematosus (SLE) is a significant risk factor for cardiovascular disease. The relationship between SLE and perioperative cardiovascular risks following non-cardiac surgery is uncertain. We investigated associations between a diagnosis of SLE and outcomes following major non-cardiac surgery in a large national database from the United States. Patients age ≥ 18 years requiring major non-cardiac surgery were identified from Healthcare Cost and Utilization Project's National Inpatient Sample data from 2004 to 2014...
January 2018: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/29145701/editorial-tumor-necrosis-factor-antagonists-killing-two-birds-with-one-biologic-stone
#11
EDITORIAL
Joan M Bathon, Jon T Giles, Daniel H Solomon
No abstract text is available yet for this article.
March 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29142034/cumulative-burden-of-glucocorticoid-related-adverse-events-in-patients-with-systemic-lupus-erythematosus-findings-from-a-12-year-longitudinal-study
#12
Hung-Lin Chen, Li-Jiuan Shen, Ping-Ning Hsu, Chieh-Yu Shen, Susan A Hall, Fei-Yuan Hsiao
OBJECTIVE: The aim of this population-based study is to examine the adverse events (AE) associated with longitudinal systemic glucocorticoid (GC) use among an ethnic Chinese systemic lupus erythematosus (SLE) cohort. METHODS: Our study subjects were patients with newly diagnosed SLE aged 18 and older who received at least 1 prescription of systemic GC between 2001 and 2012 from Taiwan's National Health Insurance Research Database (NHIRD). The earliest prescription date of systemic GC for each subject was defined as the index date...
January 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29094181/cardiovascular-disease-in-patients-with-autoinflammatory-syndromes
#13
REVIEW
Rainer Hintenberger, Agnes Falkinger, Kathrin Danninger, Herwig Pieringer
Autoinflammatory syndromes (AIS) are characterized by recurring events of inflammation, leading to a variety of organ manifestations and fever attacks. A subgroup of AIS is commonly referred to as hereditary periodic fever syndromes (HPFS). There is substantial evidence that autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are strongly associated with cardiovascular morbidity and mortality. The link between AIS and cardiovascular disease is not that clear, even if the concept of continuous inflammation as a risk factor for cardiovascular disease is widely accepted...
January 2018: Rheumatology International
https://www.readbyqxmd.com/read/29093154/evolution-of-risk-factors-for-atherosclerotic-cardiovascular-events-in-systemic-lupus-erythematosus-a-longterm-prospective-study
#14
Konstantinos Tselios, Dafna D Gladman, Jiandong Su, Olga Ace, Murray B Urowitz
OBJECTIVE: We previously reported the effect of certain factors on cardiovascular disease (CVD) in 250 women with systemic lupus erythematosus (SLE) followed for 8 years. The aim of this study was to delineate their evolution after 15 years of followup. METHODS: There were 210 women with SLE and 138 age-matched healthy women available for analysis after 15 years. Cardiovascular events (CVE) included angina pectoris, myocardial infarction (fatal and nonfatal), transient ischemic attack, and stroke (fatal and nonfatal)...
December 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29038899/the-use-of-primary-prevention-statin-therapy-in-those-predisposed-to-atherosclerosis
#15
REVIEW
Michael Garshick, James A Underberg
PURPOSE OF REVIEW: Many guidelines exist for the use of statins in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Few have focused on disease specific states that predispose to ASCVD. This review is intended to focus on the recommendations and evidence in inflammatory diseases that predispose to an increased risk of ASCVD beyond what conventional cardiac risk scores would predict. RECENT FINDINGS: Certain autoimmune inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematous (SLE), and psoriasis/psoriatic arthritis have all been shown to increase the risk of ASCVD...
October 17, 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/28993952/discordance-of-the-framingham-cardiovascular-risk-score-and-the-2013-american-college-of-cardiology-american-heart-association-risk-score-in-systemic-lupus-erythematosus-and-rheumatoid-arthritis
#16
Kashif Jafri, Alexis Ogdie, Atif Qasim, Sarah L Patterson, Milena Gianfrancesco, Zara Izadi, Patricia Katz, Jinoos Yazdany, Gabriela Schmajuk
Despite the increasing use of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cardiovascular (CV) risk score in clinical practice, few studies have compared this score to the Framingham risk score among rheumatologic patients. We calculated Framingham and 2013 ACC/AHA risk scores in subjects with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and assessed demographic, CV, and rheumatologic characteristics associated with discordant scores (high-risk ACC/AHA scores but low-risk Framingham scores)...
February 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/28974909/age-adjusted-charlson-comorbidity-index-scores-predict-major-adverse-cardiovascular-events-and-all-cause-mortality-among-systemic-lupus-erythematosus-patients
#17
Mei-Hua Chuang, Tzyy-Ling Chuang, Kuang-Yung Huang, Yuh-Feng Wang
OBJECTIVE: Cardiovascular events are the most frequent cause of death or disability among people with systemic lupus erythematosus (SLE). However, the causes of this increased the risk of major adverse cardiovascular events (MACEs) are not completely understood. The Age-adjusted Charlson Comorbidity Index (ACCI) is a prognostic classification that was initially developed for patients who have a number of comorbid conditions and the ACCI has been validated in many clinical settings. MATERIALS AND METHODS: In this study, 5998 patients were enrolled from the National Health Research Institute Database of Taiwan...
July 2017: Ci Ji Yi Xue za Zhi, Tzu-chi Medical Journal
https://www.readbyqxmd.com/read/28840094/the-risk-benefit-ratio-of-glucocorticoids-in-sle-have-things-changed-over-the-past-40-years
#18
G Stojan, M Petri
PURPOSE OF REVIEW: Glucocorticoids have been the mainstay of treatment in systemic lupus erythematosus for more than half a century. Despite advancements in knowledge concerning the pathophysiology of systemic lupus, the genomic/non-genomic actions of glucocorticoids, and the use of novel therapeutic agents in SLE, the burden of toxicity from glucocorticoid use remains unchanged. RECENT FINDINGS: SLE patients receiving long-term prednisone therapy are at significant risk of morbidity due to permanent organ damage and prednisone daily dosages above 6 mg have been shown to increase the risk of future organ damage by 50%...
September 2017: Current Treatment Options in Rheumatology
https://www.readbyqxmd.com/read/28837372/update-upon-efficacy-and-safety-of-etanercept-for-the-treatment-of-spondyloarthritis-and-juvenile-idiopathic-arthritis
#19
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio, Rossella Gulli, Paola Mandich, Francesco Puppo
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept...
May 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/28762647/renal-histology-in-indigenous-australians-with-lupus-nephritis
#20
Farshad Ghazanfari, Zulfikar Jabbar, Johannes Nossent
BACKGROUND: Lupus nephritis (LN) is a feared complication of systemic lupus erythematosus (SLE). Renal biopsy is valuable to assess disease severity and prognosis, but no histological data are available for Indigenous Australians (IA). We compared histopathology between IA and non-IA patients (NI) with LN in northern Australia and describe main outcomes. METHODS: Retrospective cohort study of all patients with biopsy evidence of LN at Royal Darwin Hospital over a 10-year period...
January 2018: International Journal of Rheumatic Diseases
keyword
keyword
95169
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"